#BEGIN_DRUGCARD DB00290

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01DC01

# Absorption:
Systemic absorption is approximately 45%.

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Blenoxane
Bleo

# CAS_Registry_Number:
11056-06-7

# ChEBI_ID:
22907

# Chemical_Formula:
C55H84N17O21S3

# Chemical_IUPAC_Name:
(3-{[2-(2-{2-[(2S,3R)-2-[(2S,3S,4R)-4-[(2S,3R)-2-({6-amino-2-[(1S)-1-{[(2S)-2-amino-2-carbamoylethyl]amino}-2-carbamoylethyl]-5-methylpyrimidin-4-yl}formamido)-3-[(3-{[4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-3-(1H-imidazol-5-yl)propanamido]-3-hydroxy-2-methylpentanamido]-3-hydroxybutanamido]ethyl}-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]formamido}propyl)dimethylsulfanium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2131692

# Description:
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.

# Dosage_Forms:
Powder, for solution	Intravenous

# Drug_Category:
Antibiotics, Antineoplastic
Antimetabolites

# Drug_Interactions:
BRENTUXIMAB VEDOTIN	Pulmonary toxicity of bleomycin may be increased. Avoid combination.
Digoxin	The antineoplasic agent decreases the effect of digoxin
Fosphenytoin	The antineoplasic agent decreases the effect of hydantoin
Leflunomide	Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity.
Natalizumab	Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
Phenytoin	The antineoplasic agent decreases the effect of hydantoin
Pimecrolimus	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants like bleomycin. This combination is contraindicated
Roflumilast	Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning.
Tacrolimus	Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
11749501	Claussen CA, Long EC: Nucleic Acid recognition by metal complexes of bleomycin. Chem Rev. 1999 Sep 8;99(9):2797-816.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Bleomycin

# HET_ID:
BLM

# Half_Life:
115 minutes

# InChI_Identifier:
InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1

# InChI_Key:
InChIKey=OYVAGSVQBOHSSS-WXFSZRTFSA-O

# Indication:
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.

# KEGG_Compound_ID:
C06854

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
290

# Mechanism_Of_Action:
Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. It is believed that bleomycin chelates  metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.

# Melting_Point:
71 Â°C

# Molecular_Weight_Avg:
1415.552

# Molecular_Weight_Mono:
1414.518979905

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1XRK

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448645

# Pharmacology:
Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown <i>in vitro</i> to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).

# Predicted_LogP_Hydrophobicity:
-0.52

# Predicted_LogS:
-4.7

# Predicted_Water_Solubility:
2.82e-02 g/l

# Primary_Accession_No:
DB00290

# Protein_Binding:
1%

# PubChem_Compound_ID:
5360373

# PubChem_Substance_ID:
46509116

# RxList_Link:
http://www.rxlist.com/cgi/generic3/bleomycin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00453
EXPT00718

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
BLM
Bleocin
Bleomicin
Bleomicina [INN-Spanish]
Bleomycin A2
Bleomycin sulfate
Bleomycine [INN-French]
Bleomycinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.

# Update_Date:
2013-02-08 16:19:14 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Bleomycin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_1_ID:
7247

# Phase_1_Metabolizing_Enzyme_1_Name:
Bleomycin hydrolase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
Q13867

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17202402	Rose JL, Reeves KC, Likhotvorik RI, Hoyt DG: Base excision repair proteins are required for integrin-mediated suppression of bleomycin-induced DNA breakage in murine lung endothelial cells. J Pharmacol Exp Ther. 2007 Apr;321(1):318-26. Epub 2007 Jan 3.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
LIG1

# Drug_Target_1_GenBank_ID_Gene:
M36067

# Drug_Target_1_GenBank_ID_Protein:
187143

# Drug_Target_1_GeneCard_ID:
LIG1

# Drug_Target_1_Gene_Name:
LIG1

# Drug_Target_1_Gene_Sequence:
>2760 bp
ATGCAGCGAAGTATCATGTCATTTTTCCACCCCAAGAAAGAGGGTAAAGCAAAGAAGCCT
GAGAAGGAGGCATCCAATAGCAGCAGAGAGACGGAGCCCCCTCCAAAGGCGGCACTGAAG
GAGTGGAATGGAGTGGTGTCCGAGAGTGACTCTCCGGTGAAGAGGCCAGGGAGGAAGGCG
GCCCGGGTCCTGGGCAGCGAAGGGGAAGAGGAGGATGAAGCCCTTAGCCCTGCTAAAGGC
CAGAAGCCTGCCCTGGACTGCTCACAGGTCTCCCCGCCCCGTCCTGCCACATCTCCTGAG
AACAATGCTTCCCTCTCTGACACCTCTCCCATGGACAGTTCCCCATCAGGGATTCCGAAG
CGTCGCACAGCTCGGAAGCAGCTCCCGAAACGGACCATTCAGGAAGTCCTGGAAGAGCAG
AGTGAGGACGAGGACAGAGAAGCCAAGAGGAAGAAGGAGGAGGAAGAAGAGGAGACCCCG
AAAGAAAGCCTCACAGAGGCTGAAGTGGCAACAGAGAAGGAAGGAGAAGACGGGGACCAG
CCCACCACGCCTCCCAAGCCCCTAAAGACCTCCAAAGCAGAGACCCCGACGGAAAGCGTT
TCAGAGCCTGAGGTGGCCACGAAGCAGGAACTGCAGGAGGAGGAAGAGCAGACCAAGCCT
CCCCGCAGAGCTCCCAAGACGCTCAGCAGCTTCTTCACCCCCCGGAAGCCAGCAGTCAAA
AAAGAAGTGAAGGAAGAGGAGCCAGGGGCTCCAGGAAAGGAGGGAGCTGCTGAGGGACCC
CTGGATCCATCTGGTTACAATCCTGCCAAGAACAACTATCATCCCGTGGAAGATGCCTGC
TGGAAACCGGGCCAGAAGGTTCCTTACCTGGCTGTGGCCCGGACGTTTGAGAAGATCGAG
GAGGTGTCTGCTCGGCTCCGGATGGTGGAGACGCTGAGCAACTTGCTGCGCTCCGTGGTG
GCCCTGTCGCCTCCAGACCTCCTCCCTGTCCTCTACCTCAGCCTCAACCACCTTGGGCCA
CCCCAGCAGGGCCTGGAGCTTGGCGTGGGTGATGGTGTCCTTCTCAAGGCAGTGGCCCAG
GCCACAGGTCGGCAGCTGGAGTCCGTCCGGGCTGAGGCAGCCGAGAAAGGCGACGTGGGG
CTGGTGGCCGAGAACAGCCGCAGCACCCAGAGGCTCATGCTGCCACCACCTCCGCTCACT
GCCTCCGGGGTCTTCAGCAAGTTCCGCGACATCGCCAGGCTCACTGGCAGTGCTTCCACA
GCCAAGAAGATAGACATCATCAAAGGCCTCTTTGTGGCCTGCCGCCACTCAGAAGCCCGG
TTCATCGCTAGGTCCCTGAGCGGACGGCTGCGCCTTGGGCTGGCAGAGCAGTCGGTGCTG
GCTGCCCTCTCCCAGGCAGTGAGCCTCACGCCCCCGGGCCAAGAATTCCCACCAGCCATG
GTGGATGCTGGGAAGGGCAAGACAGCAGAGGCCAGAAAGACGTGGCTGGAGGAGCAAGGC
ATGATCCTGAAGCAGACGTTCTGCGAGGTTCCCGACCTGGACCGAATTATCCCCGTGCTG
CTGGAGCACGGCCTGGAACGTCTCCCGGAGCACTGCAAGCTGAGCCCAGGGATTCCCCTG
AAACCAATGTTGGCCCATCCCACCCGGGGCATCAGCGAGGTCCTGAAACGCTTTGAGGAG
GCAGCTTTCACCTGCGAATACAAATATGACGGGCAGAGGGCACAGATCCACGCCCTGGAA
GGCGGGGAGGTGAAGATCTTCAGCAGGAATCAGGAAGACAACACTGGGAAGTACCCGGAC
ATCATCAGCCGCATCCCCAAGATTAAACTCCCATCGGTCACATCCTTCATCCTGGACACC
GAAGCCGTGGCTTGGGACCGGGAAAAGAAGCAGATCCAGCCATTCCAAGTGCTCACCACC
CGCAAACGCAAGGAGGTGGATGCGTCTGAGATCCAGGTGCAGGTGTGTTTGTACGCCTTC
GACCTCATCTACCTCAATGGAGAGTCCCTGGTACGTGAGCCCCTTTCCCGGCGCCGGCAG
CTGCTCCGGGAGAACTTTGTGGAGACAGAGGGCGAGTTTGTCTTCGCCACCTCCCTGGAC
ACCAAGGACATCGAGCAGATCGCCGAGTTCCTGGAGCAGTCAGTGAAAGACTCCTGCGAG
GGGCTGATGGTGAAGACCCTGGATGTTGATGCCACCTACGAGATCGCCAAGAGATCGCAC
AACTGGCTCAAGCTGAAGAAGGACTACCTTGATGGCGTGGGTGACACCCTGGACCTGGTG
GTGATCGGCGCCTACCTGGGCCGGGGGAAGCGGGCCGGCCGGTACGGGGGCTTCCTGCTG
GCCTCCTACGACGAGGACAGTGAGGAGCTGCAGGCCATATGCAAGCTTGGAACTGGCTTC
AGTGATGAGGAGCTGGAGGAGCATCACCAGAGCCTCAAGGCGCTGGTGCTGCCCAGCCCA
CGCCCTTACGTGCGGATAGATGGCGCTGTGATTCCCGACCACTGGCTGGACCCCAGCGCT
GTGTGGGAGGTGAAGTGCGCTGACCTCTCCCTCTCTCCCATCTACCCTGCTGCGCGGGGC
CTGGTGGATAGTGACAAGGGCATCTCCCTTCGCTTCCCTCGGTTTATTCGAGTCCGTGAA
GACAAGCAGCCGGAGCAGGCCACCACCAGTGCTCAGGTGGCCTGTTTGTACCGGAAGCAA
AGTCAGATTCAGAACCAACAAGGCGAGGACTCAGGCTCTGACCCTGAAGATACCTACTAA

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
1581963	Barnes DE, Tomkinson AE, Lehmann AR, Webster AD, Lindahl T: Mutations in the DNA ligase I gene of an individual with immunodeficiencies and cellular hypersensitivity to DNA-damaging agents. Cell. 1992 May 1;69(3):495-503.
1881902	Petrini JH, Huwiler KG, Weaver DT: A wild-type DNA ligase I gene is expressed in Bloom's syndrome cells. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7615-9.
2204063	Barnes DE, Johnston LH, Kodama K, Tomkinson AE, Lasko DD, Lindahl T: Human DNA ligase I cDNA: cloning and functional expression in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6679-83.

# Drug_Target_1_HGNC_ID:
HGNC:6598

# Drug_Target_1_HPRD_ID:
00534

# Drug_Target_1_ID:
222

# Drug_Target_1_Locus:
19q13.2-q13.3

# Drug_Target_1_Molecular_Weight:
101737

# Drug_Target_1_Name:
DNA ligase 1

# Drug_Target_1_Number_of_Residues:
919

# Drug_Target_1_PDB_ID:
1X9N

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01068	DNA_ligase_A_M
PF04675	DNA_ligase_A_N
PF04679	DNA_ligase_A_C

# Drug_Target_1_Protein_Sequence:
>DNA ligase 1
MQRSIMSFFHPKKEGKAKKPEKEASNSSRETEPPPKAALKEWNGVVSESDSPVKRPGRKA
ARVLGSEGEEEDEALSPAKGQKPALDCSQVSPPRPATSPENNASLSDTSPMDSSPSGIPK
RRTARKQLPKRTIQEVLEEQSEDEDREAKRKKEEEEEETPKESLTEAEVATEKEGEDGDQ
PTTPPKPLKTSKAETPTESVSEPEVATKQELQEEEEQTKPPRRAPKTLSSFFTPRKPAVK
KEVKEEEPGAPGKEGAAEGPLDPSGYNPAKNNYHPVEDACWKPGQKVPYLAVARTFEKIE
EVSARLRMVETLSNLLRSVVALSPPDLLPVLYLSLNHLGPPQQGLELGVGDGVLLKAVAQ
ATGRQLESVRAEAAEKGDVGLVAENSRSTQRLMLPPPPLTASGVFSKFRDIARLTGSAST
AKKIDIIKGLFVACRHSEARFIARSLSGRLRLGLAEQSVLAALSQAVSLTPPGQEFPPAM
VDAGKGKTAEARKTWLEEQGMILKQTFCEVPDLDRIIPVLLEHGLERLPEHCKLSPGIPL
KPMLAHPTRGISEVLKRFEEAAFTCEYKYDGQRAQIHALEGGEVKIFSRNQEDNTGKYPD
IISRIPKIKLPSVTSFILDTEAVAWDREKKQIQPFQVLTTRKRKEVDASEIQVQVCLYAF
DLIYLNGESLVREPLSRRRQLLRENFVETEGEFVFATSLDTKDIEQIAEFLEQSVKDSCE
GLMVKTLDVDATYEIAKRSHNWLKLKKDYLDGVGDTLDLVVIGAYLGRGKRAGRYGGFLL
ASYDEDSEELQAICKLGTGFSDEELEEHHQSLKALVLPSPRPYVRIDGAVIPDHWLDPSA
VWEVKCADLSLSPIYPAARGLVDSDKGISLRFPRFIRVREDKQPEQATTSAQVACLYRKQ
SQIQNQQGEDSGSDPEDTY

# Drug_Target_1_Reaction:
ATP + (deoxyribonucleotide)n + (deoxyribonucleotide)m = AMP + diphosphate + (deoxyribonucleotide)n+m

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This protein seals, during DNA replication, DNA recombination and DNA repair, nicks in double-stranded DNA

# Drug_Target_1_SwissProt_ID:
P18858

# Drug_Target_1_SwissProt_Name:
DNLI1_HUMAN

# Drug_Target_1_Synonyms:
DNA ligase I
EC 6.5.1.1
Polydeoxyribonucleotide synthase [ATP] 1

# Drug_Target_1_Theoretical_pI:
5.30

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
18597467	Akiyama Y, Ma Q, Edgar E, Laikhter A, Hecht SM: Identification of strong DNA binding motifs for bleomycin. J Am Chem Soc. 2008 Jul 30;130(30):9650-1. Epub 2008 Jul 3.
18757754	Chow MS, Liu LV, Solomon EI: Further insights into the mechanism of the reaction of activated bleomycin with DNA. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13241-5. Epub 2008 Aug 29.
19146404	Ma Q, Akiyama Y, Xu Z, Konishi K, Hecht SM: Identification and cleavage site analysis of DNA sequences bound strongly by bleomycin. J Am Chem Soc. 2009 Feb 11;131(5):2013-22.
6177398	Mirabelli CK, Ting A, Huang CH, Mong S, Crooke ST: Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_2_General_Function:
Biological information storage and information transfer

# Drug_Target_2_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
874

# Drug_Target_2_Locus:
All loci

# Drug_Target_2_Molecular_Weight:
7656 (double strand)

# Drug_Target_2_Name:
DNA

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
1BNA

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_2_SwissProt_ID:
Not Available

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Deoxyribonucleic acid

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Nucleus

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17202402	Rose JL, Reeves KC, Likhotvorik RI, Hoyt DG: Base excision repair proteins are required for integrin-mediated suppression of bleomycin-induced DNA breakage in murine lung endothelial cells. J Pharmacol Exp Ther. 2007 Apr;321(1):318-26. Epub 2007 Jan 3.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
LIG3

# Drug_Target_3_GenBank_ID_Gene:
X84740

# Drug_Target_3_GenBank_ID_Protein:
860963

# Drug_Target_3_GeneCard_ID:
LIG3

# Drug_Target_3_Gene_Name:
LIG3

# Drug_Target_3_Gene_Sequence:
>2769 bp
ATGGCTGAGCAACGGTTCTGTGTGGACTATGCCAAGCGTGGCACAGCTGGCTGCAAAAAA
TGCAAGGAAAAGATTGTGAAGGGCGTATGCCGAATTGGCAAAGTGGTGCCCAATCCCTTC
TCAGAGTCTGGGGGTGATATGAAAGAGTGGTACCACATTAAATGCATGTTTGAGAAACTA
GAGCGGGCCCGGGCCACCACAAAAAAAATCGAGGACCTCACAGAGCTGGAAGGCTGGGAA
GAGCTGGAAGATAATGAGAAGGAACAGATAACCCAGCACATTGCAGATCTGTCTTCTAAG
GCAGCAGGTACACCAAAGAAGAAAGCTGTTGTCCAGGCTAAGTTGACAACCACTGGCCAG
GTGACTTCTCCAGTGAAAGGCGCCTCATTTGTCACCAGTACCAATCCCCGGAAATTTTCT
GGCTTTTCAGCCAAGCCCAACAACTCTGGGGAAGCCCCCTCGAGCCCCACCCCTAAGAGA
AGTCTGTCTTCAAGCAAATGTGACCCCAGGCATAAGGACTGTCTGCTACGGGAGTTTCGA
AAGTTATGCGCCATGGTGGCCGATAATCCTAGCTACAACACGAAGACCCAGATCATCCAG
GACTTCCTTCGGAAAGGCTCAGCAGGAGATGGTTTCCACGGTGATGTGTACCTAACAGTG
AAGCTGCTGCTGCCAGGAGTCATTAAGACTGTTTACAACTTGAACGATAAGCAGATTGTG
AAGCTTTTCAGTCGCATTTTTAACTGCAACCCAGATGATATGGCACGGGACCTAGAGCAG
GGTGACGTGTCAGAGACAATCAGAGTCTTCTTTGAGCAGAGCAAGTCTTTCCCCCCAGCT
GCCAAGAGCCTCCTTACCATCCAGGAAGTGGATGAGTTCCTTCTGCGGCTGTCCAAGCTC
ACCAAGGAGGATGAGCAGCAACAGGCCCTACAGGACATTGCCTCCAGGTGTACAGCCAAT
GACCTTAAATGCATCATCAGGTTGATCAAACATGATCTGAAGATGAACTCAGGTGCAAAA
CATGTGTTAGACGCCCTTGACCCCAATGCCTATGAAGCCTTCAAAGCCTCGCGCAACCTG
CAGGATGTGGTGGAGCGGGTCCTTCACAACGCGCAGGAGGTGGAGAAGGAGCCGGGCCAG
AGACGAGCTCTGAGCGTCCAGGCCTCGCTGATGACACCTGTGCAGCCCATGTTGGCGGAG
GCCTGCAAGTCCGTTGAGTATGCAATGAAGAAATGTCCCAATGGCATGTTCTCTGAGATC
AAGTACGATGGAGAGCGAGTCCAGGTGCATAAGAATGGAGACCACTTCAGCTACTTCAGC
CGCAGTCTCAAGCCCGTCCTTCCTCACAAGGTGGCCCACTTTAAGGACTACATTCCCCAG
GCTTTTCCTGGGGGCCACAGCATGATCTTGGATTCTGAAGTGCTTCTGATTGACAACAAG
ACAGGCAAACCACTGCCCTTTGGGACTCTGGGAGTACACAAGAAAGCAGCCTTCCAGGAT
GCTAATGTCTGCCTGTTTGTTTTTGATTGTATCTACTTTAATGATGTCAGCTTGATGGAC
AGACCTCTGTGTGAGCGGCGGAAGTTTCTTCATGACAACATGGTTGAAATTCCAAACCGG
ATCATGTTCTCAGAAATGAAGCGAGTCACAAAAGCTTTGGACTTGGCTGACATGATAACC
CGGGTGATCCAGGAGGGATTGGAGGGGCTGGTGCTGAAGGATGTGAAGGGTACATATGAG
CCTGGGAAGCGGCACTGGCTGAAAGTGAAGAAAGACTATTTGAACGAGGGGGCCATGGCC
GACACAGCTGACCTGGTGGTCCTTGGAGCCTTCTATGGGCAAGGGAGCAAAGGCGGCATG
ATGTCAATCTTCCTCATGGGCTGCTACGACCCTGGCAGCCAGAAGTGGTGCACAGTCACC
AAGTGTGCAGGAGGCCATGATGATGCCACGCTTGCCCGCCTGCAGAATGAACTAGACATG
GTGAAGATCAGCAAGGACCCCAGCAAAATACCCAGCTGGTTGAAGGTCAACAAGATCTAC
TATCCTGACTTCATCGTCCCAGACCCAAAGAAAGCTGCCGTGTGGGAGATCACAGGGGCT
GAATTCTCCAAATCGGAGGCTCATACAGCTGACGGGATCTCCATCCGATTCCCTCGCTGC
ACCCGAATCCGAGATGATAAGGACTGGAAATCTGCCACTAACCTTCCCCAACTCAAGGAA
CTGTACCAGTTGTCCAAGGAGAAGGCAGACTTCACTGTAGTGGCTGGAGATGAGGGGAGC
TCCACTACAGGGGGTAGCAGTGAAGAGAATAAGGGTCCCTCAGGGTCTGCTGTGTCCCGC
AAGGCCCCCAGCAAGCCCTCAGCCAGTACCAAGAAAGCAGAAGGGAAGCTGAGTAACTCC
AACAGCAAAGATGGCAACATGCAGACTGCAAAGCCTTCCGCTATGAAGGTGGGGGAGAAG
CTGGCCACAAAGTCTTCTCCAGTGAAAGTAGGGGAGAAGCGGAAAGCTGCTGATGAGACG
CTGTGCCAAACAAAGGTATTGCTGGACATCTTCACTGGGGTGCGGCTTTACTTGCCACCC
TCCACACCAGACTTCAGCCGTCTCAGACGCTACTTTGTGGCATTCGACGGGGACCTGGTA
CAGGAATTTGATATGACTTCAGCCACGCACGTGCTGGGTAGCAGGGACAAGAACCCTGCG
GCCCAGCAGGTCTCCCCAGAGTGGATTTGGGCATGTATCCGGAAACGGAGACTGGTAGCT
CCCTGCTAG

# Drug_Target_3_General_Function:
Replication, recombination and repair

# Drug_Target_3_General_References:
7565692	Chen J, Tomkinson AE, Ramos W, Mackey ZB, Danehower S, Walter CA, Schultz RA, Besterman JM, Husain I: Mammalian DNA ligase III: molecular cloning, chromosomal localization, and expression in spermatocytes undergoing meiotic recombination. Mol Cell Biol. 1995 Oct;15(10):5412-22.
7760816	Wei YF, Robins P, Carter K, Caldecott K, Pappin DJ, Yu GL, Wang RP, Shell BK, Nash RA, Schar P, et al.: Molecular cloning and expression of human cDNAs encoding a novel DNA ligase IV and DNA ligase III, an enzyme active in DNA repair and recombination. Mol Cell Biol. 1995 Jun;15(6):3206-16.

# Drug_Target_3_HGNC_ID:
HGNC:6600

# Drug_Target_3_HPRD_ID:
02966

# Drug_Target_3_ID:
187

# Drug_Target_3_Locus:
17q11.2-q12

# Drug_Target_3_Molecular_Weight:
102692

# Drug_Target_3_Name:
DNA ligase 3

# Drug_Target_3_Number_of_Residues:
922

# Drug_Target_3_PDB_ID:
1UW0

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00645	zf-PARP
PF01068	DNA_ligase_A_M
PF04675	DNA_ligase_A_N
PF04679	DNA_ligase_A_C

# Drug_Target_3_Protein_Sequence:
>DNA ligase 3
MAEQRFCVDYAKRGTAGCKKCKEKIVKGVCRIGKVVPNPFSESGGDMKEWYHIKCMFEKL
ERARATTKKIEDLTELEGWEELEDNEKEQITQHIADLSSKAAGTPKKKAVVQAKLTTTGQ
VTSPVKGASFVTSTNPRKFSGFSAKPNNSGEAPSSPTPKRSLSSSKCDPRHKDCLLREFR
KLCAMVADNPSYNTKTQIIQDFLRKGSAGDGFHGDVYLTVKLLLPGVIKTVYNLNDKQIV
KLFSRIFNCNPDDMARDLEQGDVSETIRVFFEQSKSFPPAAKSLLTIQEVDEFLLRLSKL
TKEDEQQQALQDIASRCTANDLKCIIRLIKHDLKMNSGAKHVLDALDPNAYEAFKASRNL
QDVVERVLHNAQEVEKEPGQRRALSVQASLMTPVQPMLAEACKSVEYAMKKCPNGMFSEI
KYDGERVQVHKNGDHFSYFSRSLKPVLPHKVAHFKDYIPQAFPGGHSMILDSEVLLIDNK
TGKPLPFGTLGVHKKAAFQDANVCLFVFDCIYFNDVSLMDRPLCERRKFLHDNMVEIPNR
IMFSEMKRVTKALDLADMITRVIQEGLEGLVLKDVKGTYEPGKRHWLKVKKDYLNEGAMA
DTADLVVLGAFYGQGSKGGMMSIFLMGCYDPGSQKWCTVTKCAGGHDDATLARLQNELDM
VKISKDPSKIPSWLKVNKIYYPDFIVPDPKKAAVWEITGAEFSKSEAHTADGISIRFPRC
TRIRDDKDWKSATNLPQLKELYQLSKEKADFTVVAGDEGSSTTGGSSEENKGPSGSAVSR
KAPSKPSASTKKAEGKLSNSNSKDGNMQTAKPSAMKVGEKLATKSSPVKVGEKRKAADET
LCQTKVLLDIFTGVRLYLPPSTPDFSRLRRYFVAFDGDLVQEFDMTSATHVLGSRDKNPA
AQQVSPEWIWACIRKRRLVAPC

# Drug_Target_3_Reaction:
ATP + (deoxyribonucleotide)n + (deoxyribonucleotide)m = AMP + diphosphate + (deoxyribonucleotide)n+m

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Interacts with DNA-repair protein XRCC1 and can correct defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents

# Drug_Target_3_SwissProt_ID:
P49916

# Drug_Target_3_SwissProt_Name:
DNLI3_HUMAN

# Drug_Target_3_Synonyms:
DNA ligase III
EC 6.5.1.1
Polydeoxyribonucleotide synthase [ATP] 3

# Drug_Target_3_Theoretical_pI:
9.17

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00290
